BINEX Co (053030) Fair Value & Analysis
Healthcare · KR · Market cap 261B KRW
Fair value as of: Jul 6, 2026
From 4 valuation models · updated today
Fair value updated Jul 6, 2026 — revised from 27,024 KRW to 1,844 KRW (−93.2%) since Jun 24, 2026. Share price −12.6% over the past month.
Price vs Fair Value (12 months)
12‑month range 6,800 KRW – 18,490 KRW · fair‑value band 794.01 KRW – 2,895 KRW · the 7,430 KRW price screens above the 1,844 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BINEX Co (053030) currently trades at 7,430 KRW, while our model-based Fair Value estimate is 1,844 KRW — implying the stock looks roughly 75.2% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, BINEX Co generated revenue of 155B KRW at a net margin of 10.7%. Revenue grew 18.3% year over year. Net debt stands at 73.5B KRW. Fundamentals as of Jul 6, 2026
Our scenario range runs from 794.01 KRW (bear case) to 2,895 KRW (bull case); at 7,430 KRW, the current price sits above that range. The share trades about 61% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -12% fair-value upside — at -75%, 053030 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BINEX Co reported revenue of 168B KRW in FY2025 versus 134B KRW in FY2021, a compound +5.8%/yr. Reported net income was −3.2B KRW in FY2025.
Is 053030 fairly valued? → Check now
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ST Pharm Co 237690 | 115,900 KRW | 61,182 KRW | -47% |
| NatureCell Co 007390 | 33,950 KRW | 901.89 KRW | -97% |
| Oscotec Inc 039200 | 38,950 KRW | 34,117 KRW | -12% |
| DongKook Pharmaceutical Co 086450 | 17,280 KRW | 25,989 KRW | +50% |
| Kolon Life Science Inc 102940 | 49,200 KRW | 48,134 KRW | -2% |
| Komipharm International Co 041960 | 8,370 KRW | 543.06 KRW | -94% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 22,700 KRW | 49,475 KRW | +118% |
| Vivozon Pharmaceutical Co 082800 | 2,765 KRW | 2,928 KRW | +6% |
| EURO EURO | 1.07 PHP | 0.7800 PHP | -27% |
| Prestige Biologics Co 334970 | 1,907 KRW | 564.18 KRW | -70% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BINEX Co (053030) undervalued?
What is the fair value of 053030?
What is the quality score of 053030?
What is the revenue of BINEX Co (053030)?
What is the net profit margin of 053030?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.